This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT05567796 |
|---|---|
| Status | Active not recruiting |
| Phase | Phase 3 |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 3,400 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Obesity |
| Interventions | Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide |
| Start | Nov 1, 2022 |
| Primary completion | Oct 30, 2024 |
| Study completion | Oct 19, 2026 |
| Results posted | Not yet |
| Registry last updated | Sep 30, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms.
Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| CagriSema versus placebo: Relative change in body weight | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Achievement of greater than or equal to (>=) 5% weight reduction | From baseline (week 0) to end of treatment (week 68) |
65 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
